Artificial Coma Market Insight 2030
The global artificial coma/medically induced coma market size was valued at $640.17 Million in 2020, and is projected to reach $868.63 Million by 2030, registering a CAGR of 3.1%. Medically induced coma is also known as drug-induced coma. It is induced in patients in case of traumatic brain injury, where there is a need to cure the infection. At that time doctors use certain drugs to induce coma. It is a state of unconsciousness that the body doesn’t feel pain. It is an effective shutdown of the brain activity during surgical procedure of trauma. Shutting down the function of the brain gives time to heal. In addition, there are numerous reasons to induce coma in patients with critical health issues, which includes brain infection such as meningitis and rabies.
Meningitis is an inflammation caused to brain and spinal cord. It causes swelling of the brain. Meningitis includes some types such as bacterial meningitis, viral meningitis, and fungal meningitis. In case of bacterial meningitis, bacteria enter the blood stream and travel to the brain and cause bacterial meningitis. It can be life threatening, if not treated at the right time. Therefore, it requires a surgical procedure to cure the infection. Artificial coma is an option to reduce the pain during surgery and the patient is unaware about this.
Anesthetics are used to induce coma, they are propofol and barbiturate. Propofol is a sedative agent that can be used for the induction of general anesthesia. Propofol slows down the function of the brain. It is used to sedate patients who are under critical care and require a mechanical ventilator in intensive care unit. Moreover, barbiturate is also an anesthetic drug and also called as central nervous system depressant. It is available under the brand names such as butabarbital, pentobarbital, phenobarbital and others.
Growth of the global artificial coma market is majorly driven by increase in prevalence of traumatic brain injury; increase in various types of brain infection such as meningitis; increase in cases of wound exposure that causes harm to the brain. Therefore, these aforementioned factors increase the use of anesthetics to induce coma, which drives the growth of the medical induced coma market. According to the American Heart Association Stroke Statistical Update in 2019, there were 101.5 million cases of stroke. Whereas, out of this an ischemic stroke cases was 77.2 million, intracerebral hemorrhage cases were 20.7 million. Thus, rise in burden of stroke is increasing the number of surgeries.
Traumatic brain injury is the main cause of death and disability, there were an approximately 500-800 new cases of traumatic brain injury each year in the U.S and New Zealand. These aforementioned factors led to surge in usage of anesthetics to induce coma during treatment of traumatic brain injury and are anticipated to drive the growth of the medical induced coma market. Furthermore, rise in geriatric population leads to surge in cardiovascular and chronic diseases, these factors fuel the growth of the artificial coma market. For instance, in August 2019, AstraZeneca launched propofol injectable, which is used for the maintenance of general anesthesia for mechanically ventilated patients in intensive care unit. In May 2020, Hikma Pharmaceuticals announced the launch of propofol injectable emulsion for maintenance of sedation and anesthesia. Thus, increase in usage of anesthetics during surgical procedure fuels the market growth.
The presence of key players such as neon laboratories, Claris Life Sciences, Teva Pharmaceuticals, and Piramal Healthcare, and rise in initiatives of key players in the field of new drug innovation drives the growth of the artificial coma market.
What is the Impact of COVID-19 Pandemic on the Artificial Coma Market?
The COVID-19 outbreak is anticipated to have a positive impact on the global artificial coma market. At the starting of July 2020, a few cases have been reported brain infection of meningitis with COVID-19 at the same time. Therefore, anesthetics play an important role during treatment, these aforementioned factors are anticipated to drive the artificial coma market during the forecast period.
However, the side effects associated with use of anesthetics for induced coma hinder the market growth during the forecast period.
Artificial Coma Market Segmentation
The global medical induced coma market is segmented on the basis of drug type, application, distribution channel and region. By drug type, the market is categorized into propofol and barbiturate.
On the basis of application, it is divided into status epilepticus, stroke, traumatic brain injury, brain infections, drug overdose, and others.
On the basis of distribution channel, it is divided into hospital pharmacies, and drug stores and retail pharmacies.
Region-wise, the artificial coma market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Latin America and Middle East & Africa).
Segment Review
Depending on drug type, the propofol segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to increase in R&D activities in the pharmaceutical industry, increase in number of surgeries, and surge in production of new drug launch. However, the barbiturate segment is expected to witness considerable growth during the forecast period, owing to increase in number of traumatic brain injury and increase in number of key players for development of anesthetics drug.
By Type
Propofol segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.
By application, the stroke segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to increase in prevalence of stroke. However, the status epilepticus segment is expected to witness considerable growth during the forecast period, due to increase in number of COVID-19 cases causing meningitis, rise in number of surgical procedures, and development of advanced drugs to complete the needs in healthcare.
On the basis of distribution channel, the hospital pharmacies segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to large number of key players offering various types of anesthetic drugs, increase in demand for safe care, and advancement in R&D activities for drug discovery. However, the drug stores & retail pharmacies segment is expected to witness considerable growth during the forecast period, owing to increase in cerebrovascular diseases, which can lead to stroke, or even death.
By End User
Hospitals Pharmacies segment is projected as one of the most lucrative segment.
North America garnered a major share in the artificial coma market in 2020, and is expected to continue to dominate during the forecast period, owing to rise in prevalence of traumatic brain injury, presence of key players, development of the healthcare sector, and presence of new innovative medications in the region. However, Asia-Pacific is expected to register the highest CAGR of 3.6% from 2021 to 2030, owing to increase in prevalence of geriatric population, and development of healthcare infrastructure.
The key players operating in the global artificial coma market include Astrazeneca Plc., B. Braun Melsungen, Baxter Healthcare Corporation, Dr.Reddy's Laboratories, Fresenious SE& CO., Hikma Pharmaceuticals, Pfizer Inc., Piramal Healthcare, Teva Pharmaceuticals Industries Ltd., and Viatris Inc.
By Region
Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 3.6% during the forecast period.
Key Benefits for Stakeholders
- The study provides an in-depth analysis of the medical induced coma market, and the current trends & future estimations to elucidate imminent investment pockets.
- It presents a quantitative analysis of the market from 2021 to 2030 to enable stakeholders to capitalize on the prevailing artificial coma market opportunities.
- Extensive analysis of the market based on procedures and services assists to understand the trends in the industry.
- Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the artificial coma market.
Artificial Coma/Medically Induced Coma Market Report Highlights
| Aspects | Details |
 By Type |
|
 By APPLICATION |
|
 By DISTRIBUTION CHANNEL |
|
 By Region |
|
 Key Market Players | VIATRIS INC. (MYLAN N.V), B.BRAUN MELSUNGEN AG, FRESENIUS SE & CO KGAA, DR. REDDY’S LABORATORY, ASTRAZENECA PLC, PIRAMAL GROUP, TEVA PHARMACEUTICAL INDUSTRIES LTD., HIKMA PHARMACEUTICALS, BAXTER INTERNATIONAL INC., PFIZER INC. |
Analyst Review
Increasing prevalence of stroke, rising geriatric population and increase in incidences of brain injuries, advancements in drug discovery are all attributed for growth of the artificial coma/medically induced coma market. Greater consumer awareness of and demand for preventive healthcare services, escalating demand for healthcare services from overall population and new advancements are predicted to broaden anesthetics drug’s clinical applications and increase the number of surgeries conducted.
In addition, rising surgeries related to stroke, brain infections, traumatic brain injury, status epilepticus and other disorders are expected to drive the market. Furthermore, the emergency use of propofol during surgeries contributes toward the growth of the market.
The market gains interest of healthcare companies, owing to focus on preventive facilities provide to the patients who undergoing critical surgeries, which are more complex than other health conditions. This leads to increase in utilization for anesthetics to inducing coma, thus is a great opportunity for further propelling the growth of the market.
North America is expected to witness highest growth, in terms of revenue, owing to rise in geriatric population, presence of key players, and advancements in healthcare investments. Asia-Pacific was the second largest contributor to the market in 2020, and is expected to register the fastest CAGR during the forecast period, owing to increase in incidences of sport injuries, and unmet needs for advanced drug innovation and. However, side effects associated with the use of anesthetics and stringent government policies may restrain the market growth during the forecast period.
The total market value of artificial coma market is $ 640.17 million in 2020.
The forecast period for artificial coma market is 2021 to 2030
The market value of artificial coma market in 2021 is $868.63 millon.
The base year is 2020 in artificial coma market
Top companies such as Astrazeneca Plc., B. Braun Melsungen, Baxter Healthcare Corporation, Dr.Reddy's Laboratories, Fresenius SE & CO., Hikma Pharmaceuticals, Pfizer Inc., Piramal Healthcare, Teva Pharmaceuticals Industries Ltd., and Viatris Inc.held a high market position in 2020.
Increase in development of advanced infrastructure for research & development and investments in healthcare is anticipated to drive the market in the forecast period.
Based on drug type, Propofol segment dominated the global market in 2020, and expected to continue this trend throughout the forecast period due new product launch and thus is expected to drive the segment
North America is projected to account for a major share of 48.5% the global artificial coma/medically induced coma market during the forecast period. U.S. dominated the North America rise in investments for new product launch in the R & D sector due to presence of key players across the country.
Artificial coma/medically Induced coma is a state of unconsiousness. It effectively shut down brain's activity.
Artificial coma/medically Induced coma drugs are used to induced coma during treatment of disorders such as stroke, traumatic brain injury, brain infections and status epilepticus.
Loading Table Of Content...
